Home » Stocks » Akouos

Akouos, Inc. (AKUS)

Stock Price: $21.70 USD 0.00 (0.00%)
Updated Jul 15, 2020 4:00 PM EDT - Market open
Pre-market: $21.61 -0.09 (-0.42%) Jul 15, 9:01 AM

Stock Price Chart

Key Info

Market Cap 704.85M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 28.32M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 15, 2020
Last Price $21.70
Previous Close $21.70
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 21.32 - 22.41
Day's Volume 0
52-Week Range 19.72 - 24.08

More Stats

Market Cap 704.85M
Enterprise Value 597.23M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 28.32M
Float 553,861
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 77,536
Short Ratio 0.06
Short % of Float 0.32%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 6.00
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 107.62M
Net Cash / Share 3.31
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-23.88-7.42
Net Income-25.74-6.01
Shares Outstanding0.610.47
Earnings Per Share-42.49-12.84
Operating Cash Flow-19.51-6.74
Capital Expenditures-3.44-0.53
Free Cash Flow-22.95-7.27
Cash & Equivalents26.4024.34
Total Debt13.78-
Net Cash / Debt12.6124.34
Book Value-32.80-7.23
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Akouos, Inc.
Country United States
Employees 54
CEO Emmanuel J. Simons

Stock Information

Ticker Symbol AKUS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AKUS
IPO Date June 26, 2020


Akouos, Inc., a precision genetic medicine company, develops gene therapies to restore, improve, and preserve physiologic hearing for people worldwide. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate, AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. Akouos has strategic partnerships with Massachusetts Eye and Ear and Lonza, Inc. The company was founded in 2016 and is headquartered in Boston, Massachusetts.